TWIST1 and neoplasm: To test this hypothesis, we performed experimental therapy combining Twist1 inhibition with CAR T cell infusion, in which a fully murine system we recently developed was used to specifically target tumor cells expressing mouse Egfrviii, a hallmark of GBM-associated mutation (Fig. 5A).